nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0949	0.172	CbGbCtD
Irbesartan—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0662	0.12	CbGbCtD
Irbesartan—CYP2C8—Progesterone—uterine cancer	0.0629	0.114	CbGbCtD
Irbesartan—PTGS1—Etoposide—uterine cancer	0.0488	0.0885	CbGbCtD
Irbesartan—CYP1A2—Progesterone—uterine cancer	0.0487	0.0884	CbGbCtD
Irbesartan—CYP2C9—Progesterone—uterine cancer	0.0439	0.0796	CbGbCtD
Irbesartan—CYP2D6—Progesterone—uterine cancer	0.0401	0.0728	CbGbCtD
Irbesartan—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0385	0.0699	CbGbCtD
Irbesartan—CYP2C8—Etoposide—uterine cancer	0.0281	0.0511	CbGbCtD
Irbesartan—CYP3A4—Progesterone—uterine cancer	0.0255	0.0463	CbGbCtD
Irbesartan—CYP1A2—Etoposide—uterine cancer	0.0218	0.0395	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—uterine cancer	0.0122	0.0222	CbGbCtD
Irbesartan—CYP3A4—Etoposide—uterine cancer	0.0114	0.0207	CbGbCtD
Irbesartan—JUN—oviduct—uterine cancer	0.00942	0.0892	CbGeAlD
Irbesartan—CYP3A4—Doxorubicin—uterine cancer	0.00779	0.0141	CbGbCtD
Irbesartan—JUN—artery—uterine cancer	0.00624	0.0591	CbGeAlD
Irbesartan—JUN—exocrine gland—uterine cancer	0.00544	0.0515	CbGeAlD
Irbesartan—AGTR1—artery—uterine cancer	0.0047	0.0445	CbGeAlD
Irbesartan—EDNRA—myometrium—uterine cancer	0.0033	0.0313	CbGeAlD
Irbesartan—PTGS1—oviduct—uterine cancer	0.00312	0.0295	CbGeAlD
Irbesartan—JUN—myometrium—uterine cancer	0.00301	0.0285	CbGeAlD
Irbesartan—EDNRA—uterine cervix—uterine cancer	0.00257	0.0243	CbGeAlD
Irbesartan—EDNRA—decidua—uterine cancer	0.00245	0.0232	CbGeAlD
Irbesartan—JUN—epithelium—uterine cancer	0.00237	0.0224	CbGeAlD
Irbesartan—JUN—uterine cervix—uterine cancer	0.00234	0.0222	CbGeAlD
Irbesartan—EDNRA—endometrium—uterine cancer	0.00232	0.022	CbGeAlD
Irbesartan—JUN—smooth muscle tissue—uterine cancer	0.00228	0.0216	CbGeAlD
Irbesartan—AGTR1—myometrium—uterine cancer	0.00227	0.0215	CbGeAlD
Irbesartan—EDNRA—mammalian vulva—uterine cancer	0.00225	0.0213	CbGeAlD
Irbesartan—JUN—decidua—uterine cancer	0.00223	0.0212	CbGeAlD
Irbesartan—JUN—renal system—uterine cancer	0.00219	0.0208	CbGeAlD
Irbesartan—EDNRA—uterus—uterine cancer	0.00214	0.0203	CbGeAlD
Irbesartan—JUN—endometrium—uterine cancer	0.00212	0.0201	CbGeAlD
Irbesartan—PTGS1—artery—uterine cancer	0.00207	0.0196	CbGeAlD
Irbesartan—JUN—mammalian vulva—uterine cancer	0.00205	0.0194	CbGeAlD
Irbesartan—JUN—uterus—uterine cancer	0.00195	0.0185	CbGeAlD
Irbesartan—AGTR1—epithelium—uterine cancer	0.00178	0.0169	CbGeAlD
Irbesartan—AGTR1—uterine cervix—uterine cancer	0.00177	0.0167	CbGeAlD
Irbesartan—JUN—female reproductive system—uterine cancer	0.00176	0.0166	CbGeAlD
Irbesartan—EDNRA—female gonad—uterine cancer	0.00175	0.0166	CbGeAlD
Irbesartan—EDNRA—vagina—uterine cancer	0.00174	0.0165	CbGeAlD
Irbesartan—AGTR1—smooth muscle tissue—uterine cancer	0.00172	0.0163	CbGeAlD
Irbesartan—AGTR1—decidua—uterine cancer	0.00168	0.0159	CbGeAlD
Irbesartan—AGTR1—renal system—uterine cancer	0.00165	0.0156	CbGeAlD
Irbesartan—JUN—female gonad—uterine cancer	0.0016	0.0151	CbGeAlD
Irbesartan—JUN—vagina—uterine cancer	0.00159	0.0151	CbGeAlD
Irbesartan—AGTR1—female reproductive system—uterine cancer	0.00132	0.0125	CbGeAlD
Irbesartan—AGTR1—vagina—uterine cancer	0.0012	0.0113	CbGeAlD
Irbesartan—EDNRA—lymph node—uterine cancer	0.00113	0.0107	CbGeAlD
Irbesartan—JUN—lymph node—uterine cancer	0.00103	0.00974	CbGeAlD
Irbesartan—CYP2C8—renal system—uterine cancer	0.000896	0.00848	CbGeAlD
Irbesartan—CYP2C8—endometrium—uterine cancer	0.000866	0.0082	CbGeAlD
Irbesartan—CYP1A2—renal system—uterine cancer	0.000838	0.00794	CbGeAlD
Irbesartan—PTGS1—epithelium—uterine cancer	0.000783	0.00742	CbGeAlD
Irbesartan—PTGS1—uterine cervix—uterine cancer	0.000776	0.00735	CbGeAlD
Irbesartan—AGTR1—lymph node—uterine cancer	0.000774	0.00733	CbGeAlD
Irbesartan—PTGS1—smooth muscle tissue—uterine cancer	0.000754	0.00715	CbGeAlD
Irbesartan—PTGS1—renal system—uterine cancer	0.000726	0.00688	CbGeAlD
Irbesartan—CYP2C8—female reproductive system—uterine cancer	0.000717	0.00679	CbGeAlD
Irbesartan—PTGS1—endometrium—uterine cancer	0.000702	0.00665	CbGeAlD
Irbesartan—PTGS1—mammalian vulva—uterine cancer	0.000679	0.00643	CbGeAlD
Irbesartan—CYP2C8—vagina—uterine cancer	0.000649	0.00614	CbGeAlD
Irbesartan—PTGS1—uterus—uterine cancer	0.000647	0.00613	CbGeAlD
Irbesartan—CYP2C9—female reproductive system—uterine cancer	0.000637	0.00604	CbGeAlD
Irbesartan—CYP3A4—renal system—uterine cancer	0.000607	0.00575	CbGeAlD
Irbesartan—CYP2D6—renal system—uterine cancer	0.000597	0.00565	CbGeAlD
Irbesartan—PTGS1—female reproductive system—uterine cancer	0.000582	0.00551	CbGeAlD
Irbesartan—PTGS1—female gonad—uterine cancer	0.000529	0.00501	CbGeAlD
Irbesartan—PTGS1—vagina—uterine cancer	0.000526	0.00498	CbGeAlD
Irbesartan—CYP3A4—female reproductive system—uterine cancer	0.000486	0.0046	CbGeAlD
Irbesartan—CYP2D6—female reproductive system—uterine cancer	0.000478	0.00453	CbGeAlD
Irbesartan—CYP2D6—female gonad—uterine cancer	0.000435	0.00412	CbGeAlD
Irbesartan—PTGS1—lymph node—uterine cancer	0.00034	0.00322	CbGeAlD
Irbesartan—Hypokalaemia—Epirubicin—uterine cancer	0.000203	0.000954	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000203	0.000952	CcSEcCtD
Irbesartan—Discomfort—Etoposide—uterine cancer	0.000202	0.000947	CcSEcCtD
Irbesartan—Breast disorder—Epirubicin—uterine cancer	0.000202	0.000947	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000201	0.000944	CcSEcCtD
Irbesartan—Nasopharyngitis—Epirubicin—uterine cancer	0.0002	0.000937	CcSEcCtD
Irbesartan—Face oedema—Doxorubicin—uterine cancer	0.0002	0.000936	CcSEcCtD
Irbesartan—Hypersensitivity—Dactinomycin—uterine cancer	0.0002	0.000936	CcSEcCtD
Irbesartan—Muscular weakness—Epirubicin—uterine cancer	0.000197	0.000925	CcSEcCtD
Irbesartan—Anaphylactic shock—Etoposide—uterine cancer	0.000196	0.000919	CcSEcCtD
Irbesartan—Mood swings—Doxorubicin—uterine cancer	0.000196	0.000919	CcSEcCtD
Irbesartan—Infection—Etoposide—uterine cancer	0.000195	0.000913	CcSEcCtD
Irbesartan—Abdominal distension—Epirubicin—uterine cancer	0.000195	0.000912	CcSEcCtD
Irbesartan—Asthenia—Dactinomycin—uterine cancer	0.000194	0.000911	CcSEcCtD
Irbesartan—Asthma—Epirubicin—uterine cancer	0.000193	0.000906	CcSEcCtD
Irbesartan—Dysphagia—Epirubicin—uterine cancer	0.000193	0.000906	CcSEcCtD
Irbesartan—Influenza—Epirubicin—uterine cancer	0.000193	0.000906	CcSEcCtD
Irbesartan—Thrombocytopenia—Etoposide—uterine cancer	0.000192	0.0009	CcSEcCtD
Irbesartan—Tachycardia—Etoposide—uterine cancer	0.000191	0.000897	CcSEcCtD
Irbesartan—Liver function test abnormal—Doxorubicin—uterine cancer	0.000191	0.000896	CcSEcCtD
Irbesartan—Skin disorder—Etoposide—uterine cancer	0.00019	0.000893	CcSEcCtD
Irbesartan—Hyperhidrosis—Etoposide—uterine cancer	0.00019	0.000889	CcSEcCtD
Irbesartan—Pancreatitis—Epirubicin—uterine cancer	0.000189	0.000888	CcSEcCtD
Irbesartan—Abdominal pain upper—Doxorubicin—uterine cancer	0.000189	0.000886	CcSEcCtD
Irbesartan—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000189	0.000886	CcSEcCtD
Irbesartan—Hypokalaemia—Doxorubicin—uterine cancer	0.000188	0.000883	CcSEcCtD
Irbesartan—Angina pectoris—Epirubicin—uterine cancer	0.000188	0.000883	CcSEcCtD
Irbesartan—Breast disorder—Doxorubicin—uterine cancer	0.000187	0.000877	CcSEcCtD
Irbesartan—Anorexia—Etoposide—uterine cancer	0.000187	0.000876	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000186	0.000873	CcSEcCtD
Irbesartan—Diarrhoea—Dactinomycin—uterine cancer	0.000185	0.000869	CcSEcCtD
Irbesartan—Nasopharyngitis—Doxorubicin—uterine cancer	0.000185	0.000867	CcSEcCtD
Irbesartan—Hypotension—Etoposide—uterine cancer	0.000183	0.000859	CcSEcCtD
Irbesartan—Muscular weakness—Doxorubicin—uterine cancer	0.000182	0.000856	CcSEcCtD
Irbesartan—Neutropenia—Epirubicin—uterine cancer	0.000181	0.000847	CcSEcCtD
Irbesartan—Abdominal distension—Doxorubicin—uterine cancer	0.00018	0.000844	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Epirubicin—uterine cancer	0.00018	0.000842	CcSEcCtD
Irbesartan—Asthma—Doxorubicin—uterine cancer	0.000179	0.000838	CcSEcCtD
Irbesartan—Dysphagia—Doxorubicin—uterine cancer	0.000179	0.000838	CcSEcCtD
Irbesartan—Influenza—Doxorubicin—uterine cancer	0.000179	0.000838	CcSEcCtD
Irbesartan—Photosensitivity reaction—Epirubicin—uterine cancer	0.000176	0.000827	CcSEcCtD
Irbesartan—Paraesthesia—Etoposide—uterine cancer	0.000176	0.000825	CcSEcCtD
Irbesartan—Weight increased—Epirubicin—uterine cancer	0.000176	0.000825	CcSEcCtD
Irbesartan—Pancreatitis—Doxorubicin—uterine cancer	0.000175	0.000822	CcSEcCtD
Irbesartan—Dyspnoea—Etoposide—uterine cancer	0.000175	0.00082	CcSEcCtD
Irbesartan—Hyperglycaemia—Epirubicin—uterine cancer	0.000174	0.000817	CcSEcCtD
Irbesartan—Somnolence—Etoposide—uterine cancer	0.000174	0.000817	CcSEcCtD
Irbesartan—Angina pectoris—Doxorubicin—uterine cancer	0.000174	0.000817	CcSEcCtD
Irbesartan—Pneumonia—Epirubicin—uterine cancer	0.000173	0.000813	CcSEcCtD
Irbesartan—Vomiting—Dactinomycin—uterine cancer	0.000172	0.000808	CcSEcCtD
Irbesartan—Rash—Dactinomycin—uterine cancer	0.000171	0.000801	CcSEcCtD
Irbesartan—Decreased appetite—Etoposide—uterine cancer	0.00017	0.000799	CcSEcCtD
Irbesartan—Renal failure—Epirubicin—uterine cancer	0.000169	0.000794	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Etoposide—uterine cancer	0.000169	0.000794	CcSEcCtD
Irbesartan—Fatigue—Etoposide—uterine cancer	0.000169	0.000793	CcSEcCtD
Irbesartan—Jaundice—Epirubicin—uterine cancer	0.000168	0.000787	CcSEcCtD
Irbesartan—Pain—Etoposide—uterine cancer	0.000168	0.000786	CcSEcCtD
Irbesartan—Constipation—Etoposide—uterine cancer	0.000168	0.000786	CcSEcCtD
Irbesartan—Conjunctivitis—Epirubicin—uterine cancer	0.000167	0.000785	CcSEcCtD
Irbesartan—Urinary tract infection—Epirubicin—uterine cancer	0.000167	0.000785	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—uterine cancer	0.000167	0.000784	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000166	0.000779	CcSEcCtD
Irbesartan—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000163	0.000765	CcSEcCtD
Irbesartan—Hepatobiliary disease—Epirubicin—uterine cancer	0.000163	0.000764	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—uterine cancer	0.000163	0.000763	CcSEcCtD
Irbesartan—Epistaxis—Epirubicin—uterine cancer	0.000163	0.000762	CcSEcCtD
Irbesartan—Feeling abnormal—Etoposide—uterine cancer	0.000162	0.000757	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—uterine cancer	0.000161	0.000756	CcSEcCtD
Irbesartan—Nausea—Dactinomycin—uterine cancer	0.000161	0.000754	CcSEcCtD
Irbesartan—Agranulocytosis—Epirubicin—uterine cancer	0.000161	0.000754	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—uterine cancer	0.00016	0.000752	CcSEcCtD
Irbesartan—Gastrointestinal pain—Etoposide—uterine cancer	0.00016	0.000752	CcSEcCtD
Irbesartan—Bradycardia—Epirubicin—uterine cancer	0.000157	0.000738	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—uterine cancer	0.000157	0.000735	CcSEcCtD
Irbesartan—Urticaria—Etoposide—uterine cancer	0.000156	0.00073	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—uterine cancer	0.000155	0.000729	CcSEcCtD
Irbesartan—Rhinitis—Epirubicin—uterine cancer	0.000155	0.000727	CcSEcCtD
Irbesartan—Body temperature increased—Etoposide—uterine cancer	0.000155	0.000727	CcSEcCtD
Irbesartan—Abdominal pain—Etoposide—uterine cancer	0.000155	0.000727	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—uterine cancer	0.000155	0.000727	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—uterine cancer	0.000155	0.000727	CcSEcCtD
Irbesartan—Hepatitis—Epirubicin—uterine cancer	0.000155	0.000725	CcSEcCtD
Irbesartan—Hypoaesthesia—Epirubicin—uterine cancer	0.000154	0.000722	CcSEcCtD
Irbesartan—Pharyngitis—Epirubicin—uterine cancer	0.000154	0.00072	CcSEcCtD
Irbesartan—Urinary tract disorder—Epirubicin—uterine cancer	0.000153	0.000716	CcSEcCtD
Irbesartan—Oedema peripheral—Epirubicin—uterine cancer	0.000152	0.000714	CcSEcCtD
Irbesartan—Connective tissue disorder—Epirubicin—uterine cancer	0.000152	0.000713	CcSEcCtD
Irbesartan—Urethral disorder—Epirubicin—uterine cancer	0.000152	0.000711	CcSEcCtD
Irbesartan—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000151	0.000707	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—uterine cancer	0.00015	0.000705	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—uterine cancer	0.000149	0.000699	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—uterine cancer	0.000149	0.000698	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—uterine cancer	0.000146	0.000683	CcSEcCtD
Irbesartan—Hypersensitivity—Etoposide—uterine cancer	0.000144	0.000677	CcSEcCtD
Irbesartan—Tinnitus—Epirubicin—uterine cancer	0.000144	0.000676	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—uterine cancer	0.000144	0.000673	CcSEcCtD
Irbesartan—Flushing—Epirubicin—uterine cancer	0.000144	0.000673	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—uterine cancer	0.000143	0.000673	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—uterine cancer	0.000143	0.000671	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—uterine cancer	0.000142	0.000668	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—uterine cancer	0.000142	0.000666	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—uterine cancer	0.000141	0.000663	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—uterine cancer	0.000141	0.000661	CcSEcCtD
Irbesartan—Asthenia—Etoposide—uterine cancer	0.000141	0.00066	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—uterine cancer	0.000141	0.000659	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—uterine cancer	0.00014	0.000658	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—uterine cancer	0.00014	0.000658	CcSEcCtD
Irbesartan—Immune system disorder—Epirubicin—uterine cancer	0.00014	0.000655	CcSEcCtD
Irbesartan—Mediastinal disorder—Epirubicin—uterine cancer	0.000139	0.000654	CcSEcCtD
Irbesartan—Chills—Epirubicin—uterine cancer	0.000139	0.000651	CcSEcCtD
Irbesartan—Pruritus—Etoposide—uterine cancer	0.000139	0.00065	CcSEcCtD
Irbesartan—Arrhythmia—Epirubicin—uterine cancer	0.000138	0.000648	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—uterine cancer	0.000138	0.000647	CcSEcCtD
Irbesartan—Erythema—Epirubicin—uterine cancer	0.000135	0.000631	CcSEcCtD
Irbesartan—Malnutrition—Epirubicin—uterine cancer	0.000135	0.000631	CcSEcCtD
Irbesartan—Diarrhoea—Etoposide—uterine cancer	0.000134	0.000629	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—uterine cancer	0.000133	0.000626	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—uterine cancer	0.000133	0.000623	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—uterine cancer	0.000133	0.000623	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—uterine cancer	0.000133	0.000622	CcSEcCtD
Irbesartan—Tension—Epirubicin—uterine cancer	0.000132	0.00062	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—uterine cancer	0.000132	0.000618	CcSEcCtD
Irbesartan—Nervousness—Epirubicin—uterine cancer	0.000131	0.000613	CcSEcCtD
Irbesartan—Angiopathy—Doxorubicin—uterine cancer	0.00013	0.000609	CcSEcCtD
Irbesartan—Dizziness—Etoposide—uterine cancer	0.00013	0.000608	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—uterine cancer	0.000129	0.000607	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—uterine cancer	0.000129	0.000606	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—uterine cancer	0.000129	0.000605	CcSEcCtD
Irbesartan—Chills—Doxorubicin—uterine cancer	0.000128	0.000602	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—uterine cancer	0.000128	0.000599	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—uterine cancer	0.000127	0.000595	CcSEcCtD
Irbesartan—Ill-defined disorder—Epirubicin—uterine cancer	0.000125	0.000586	CcSEcCtD
Irbesartan—Vomiting—Etoposide—uterine cancer	0.000125	0.000584	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—uterine cancer	0.000125	0.000584	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—uterine cancer	0.000125	0.000584	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—uterine cancer	0.000124	0.000584	CcSEcCtD
Irbesartan—Agitation—Epirubicin—uterine cancer	0.000124	0.00058	CcSEcCtD
Irbesartan—Rash—Etoposide—uterine cancer	0.000124	0.00058	CcSEcCtD
Irbesartan—Dermatitis—Etoposide—uterine cancer	0.000123	0.000579	CcSEcCtD
Irbesartan—Headache—Etoposide—uterine cancer	0.000123	0.000576	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—uterine cancer	0.000123	0.000576	CcSEcCtD
Irbesartan—Tension—Doxorubicin—uterine cancer	0.000122	0.000573	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—uterine cancer	0.000122	0.000572	CcSEcCtD
Irbesartan—Malaise—Epirubicin—uterine cancer	0.000121	0.000569	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—uterine cancer	0.000121	0.000567	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—uterine cancer	0.000121	0.000567	CcSEcCtD
Irbesartan—Syncope—Epirubicin—uterine cancer	0.000121	0.000566	CcSEcCtD
Irbesartan—Leukopenia—Epirubicin—uterine cancer	0.000121	0.000565	CcSEcCtD
Irbesartan—Muscle spasms—Doxorubicin—uterine cancer	0.00012	0.000562	CcSEcCtD
Irbesartan—Loss of consciousness—Epirubicin—uterine cancer	0.000118	0.000555	CcSEcCtD
Irbesartan—Cough—Epirubicin—uterine cancer	0.000117	0.000551	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—uterine cancer	0.000117	0.000551	CcSEcCtD
Irbesartan—Nausea—Etoposide—uterine cancer	0.000116	0.000546	CcSEcCtD
Irbesartan—Hypertension—Epirubicin—uterine cancer	0.000116	0.000545	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—uterine cancer	0.000116	0.000542	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—uterine cancer	0.000115	0.00054	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—uterine cancer	0.000115	0.000537	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—uterine cancer	0.000115	0.000537	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—uterine cancer	0.000115	0.000537	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—uterine cancer	0.000114	0.000537	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—uterine cancer	0.000114	0.000536	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000114	0.000534	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—uterine cancer	0.000113	0.000531	CcSEcCtD
Irbesartan—Malaise—Doxorubicin—uterine cancer	0.000112	0.000527	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—uterine cancer	0.000112	0.000526	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—uterine cancer	0.000112	0.000525	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—uterine cancer	0.000112	0.000524	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—uterine cancer	0.000112	0.000523	CcSEcCtD
Irbesartan—Oedema—Epirubicin—uterine cancer	0.00011	0.000515	CcSEcCtD
Irbesartan—Anaphylactic shock—Epirubicin—uterine cancer	0.00011	0.000515	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—uterine cancer	0.00011	0.000513	CcSEcCtD
Irbesartan—Infection—Epirubicin—uterine cancer	0.000109	0.000512	CcSEcCtD
Irbesartan—Cough—Doxorubicin—uterine cancer	0.000109	0.00051	CcSEcCtD
Irbesartan—Shock—Epirubicin—uterine cancer	0.000108	0.000507	CcSEcCtD
Irbesartan—Nervous system disorder—Epirubicin—uterine cancer	0.000108	0.000505	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—uterine cancer	0.000108	0.000504	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—uterine cancer	0.000108	0.000504	CcSEcCtD
Irbesartan—Tachycardia—Epirubicin—uterine cancer	0.000107	0.000503	CcSEcCtD
Irbesartan—Skin disorder—Epirubicin—uterine cancer	0.000107	0.0005	CcSEcCtD
Irbesartan—Hyperhidrosis—Epirubicin—uterine cancer	0.000106	0.000498	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—uterine cancer	0.000106	0.000497	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—uterine cancer	0.000106	0.000497	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—uterine cancer	0.000106	0.000497	CcSEcCtD
Irbesartan—Anxiety—Doxorubicin—uterine cancer	0.000106	0.000496	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000105	0.000494	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—uterine cancer	0.000105	0.000491	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—uterine cancer	0.000105	0.000491	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—uterine cancer	0.000104	0.000486	CcSEcCtD
Irbesartan—Hypotension—Epirubicin—uterine cancer	0.000103	0.000481	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—uterine cancer	0.000102	0.000477	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—uterine cancer	0.000102	0.000477	CcSEcCtD
Irbesartan—Infection—Doxorubicin—uterine cancer	0.000101	0.000474	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.0001	0.000469	CcSEcCtD
Irbesartan—Shock—Doxorubicin—uterine cancer	0.0001	0.000469	CcSEcCtD
Irbesartan—Nervous system disorder—Doxorubicin—uterine cancer	9.97e-05	0.000468	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—uterine cancer	9.96e-05	0.000467	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—uterine cancer	9.92e-05	0.000465	CcSEcCtD
Irbesartan—Skin disorder—Doxorubicin—uterine cancer	9.88e-05	0.000463	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—uterine cancer	9.87e-05	0.000463	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—uterine cancer	9.83e-05	0.000461	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—uterine cancer	9.8e-05	0.000459	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—uterine cancer	9.77e-05	0.000458	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—uterine cancer	9.69e-05	0.000454	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—uterine cancer	9.67e-05	0.000454	CcSEcCtD
Irbesartan—Decreased appetite—Epirubicin—uterine cancer	9.55e-05	0.000448	CcSEcCtD
Irbesartan—Hypotension—Doxorubicin—uterine cancer	9.5e-05	0.000445	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—uterine cancer	9.49e-05	0.000445	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—uterine cancer	9.47e-05	0.000444	CcSEcCtD
Irbesartan—Constipation—Epirubicin—uterine cancer	9.4e-05	0.000441	CcSEcCtD
Irbesartan—Pain—Epirubicin—uterine cancer	9.4e-05	0.000441	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—uterine cancer	9.26e-05	0.000434	CcSEcCtD
Irbesartan—Paraesthesia—Doxorubicin—uterine cancer	9.13e-05	0.000428	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—uterine cancer	9.07e-05	0.000425	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—uterine cancer	9.06e-05	0.000425	CcSEcCtD
Irbesartan—Somnolence—Doxorubicin—uterine cancer	9.04e-05	0.000424	CcSEcCtD
Irbesartan—Gastrointestinal pain—Epirubicin—uterine cancer	8.99e-05	0.000421	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—uterine cancer	8.95e-05	0.00042	CcSEcCtD
Irbesartan—Decreased appetite—Doxorubicin—uterine cancer	8.84e-05	0.000414	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—uterine cancer	8.78e-05	0.000412	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—uterine cancer	8.77e-05	0.000411	CcSEcCtD
Irbesartan—Urticaria—Epirubicin—uterine cancer	8.73e-05	0.000409	CcSEcCtD
Irbesartan—Pain—Doxorubicin—uterine cancer	8.7e-05	0.000408	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—uterine cancer	8.7e-05	0.000408	CcSEcCtD
Irbesartan—Abdominal pain—Epirubicin—uterine cancer	8.69e-05	0.000407	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—uterine cancer	8.69e-05	0.000407	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—uterine cancer	8.38e-05	0.000393	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—uterine cancer	8.31e-05	0.00039	CcSEcCtD
Irbesartan—Hypersensitivity—Epirubicin—uterine cancer	8.1e-05	0.00038	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—uterine cancer	8.08e-05	0.000379	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—uterine cancer	8.04e-05	0.000377	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—uterine cancer	8.04e-05	0.000377	CcSEcCtD
Irbesartan—Asthenia—Epirubicin—uterine cancer	7.88e-05	0.00037	CcSEcCtD
Irbesartan—Pruritus—Epirubicin—uterine cancer	7.77e-05	0.000365	CcSEcCtD
Irbesartan—Diarrhoea—Epirubicin—uterine cancer	7.52e-05	0.000353	CcSEcCtD
Irbesartan—Hypersensitivity—Doxorubicin—uterine cancer	7.49e-05	0.000351	CcSEcCtD
Irbesartan—Asthenia—Doxorubicin—uterine cancer	7.3e-05	0.000342	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—uterine cancer	7.27e-05	0.000341	CcSEcCtD
Irbesartan—Pruritus—Doxorubicin—uterine cancer	7.19e-05	0.000337	CcSEcCtD
Irbesartan—Vomiting—Epirubicin—uterine cancer	6.99e-05	0.000328	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—uterine cancer	6.96e-05	0.000326	CcSEcCtD
Irbesartan—Rash—Epirubicin—uterine cancer	6.93e-05	0.000325	CcSEcCtD
Irbesartan—Dermatitis—Epirubicin—uterine cancer	6.92e-05	0.000325	CcSEcCtD
Irbesartan—Headache—Epirubicin—uterine cancer	6.88e-05	0.000323	CcSEcCtD
Irbesartan—Dizziness—Doxorubicin—uterine cancer	6.72e-05	0.000315	CcSEcCtD
Irbesartan—Nausea—Epirubicin—uterine cancer	6.53e-05	0.000306	CcSEcCtD
Irbesartan—Vomiting—Doxorubicin—uterine cancer	6.47e-05	0.000303	CcSEcCtD
Irbesartan—Rash—Doxorubicin—uterine cancer	6.41e-05	0.000301	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—uterine cancer	6.41e-05	0.0003	CcSEcCtD
Irbesartan—Headache—Doxorubicin—uterine cancer	6.37e-05	0.000299	CcSEcCtD
Irbesartan—Nausea—Doxorubicin—uterine cancer	6.04e-05	0.000283	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—AKR1C3—uterine cancer	5e-05	0.000384	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—AKT1—uterine cancer	5e-05	0.000384	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STK11—uterine cancer	4.97e-05	0.000381	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CCL2—uterine cancer	4.95e-05	0.00038	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NDUFB11—uterine cancer	4.94e-05	0.000379	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SRD5A2—uterine cancer	4.94e-05	0.000379	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	4.93e-05	0.000378	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PGR—uterine cancer	4.88e-05	0.000374	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	4.86e-05	0.000373	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKR1C1—uterine cancer	4.86e-05	0.000373	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—AKT1—uterine cancer	4.8e-05	0.000368	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.79e-05	0.000368	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.79e-05	0.000367	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SOCS3—uterine cancer	4.65e-05	0.000357	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—YWHAE—uterine cancer	4.65e-05	0.000357	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—AKT1—uterine cancer	4.53e-05	0.000348	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.53e-05	0.000348	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	4.51e-05	0.000346	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FBXW7—uterine cancer	4.46e-05	0.000342	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CDKN2B—uterine cancer	4.45e-05	0.000342	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—POLD1—uterine cancer	4.33e-05	0.000333	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IGF1R—uterine cancer	4.32e-05	0.000332	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—STK11—uterine cancer	4.32e-05	0.000331	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CYP19A1—uterine cancer	4.32e-05	0.000331	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—CXCL8—uterine cancer	4.31e-05	0.000331	CbGpPWpGaD
Irbesartan—JUN—Immune System—SOCS3—uterine cancer	4.22e-05	0.000324	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—uterine cancer	4.12e-05	0.000317	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.09e-05	0.000314	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SMAD3—uterine cancer	4.07e-05	0.000312	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKR1C1—uterine cancer	4.05e-05	0.000311	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NDUFB11—uterine cancer	4.05e-05	0.000311	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SRD5A2—uterine cancer	4.05e-05	0.000311	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SRD5A2—uterine cancer	4.02e-05	0.000308	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NDUFB11—uterine cancer	4.02e-05	0.000308	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CXCL8—uterine cancer	3.91e-05	0.0003	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.9e-05	0.000299	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STK11—uterine cancer	3.9e-05	0.000299	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CCL2—uterine cancer	3.88e-05	0.000298	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—FGFR2—uterine cancer	3.88e-05	0.000298	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—ERBB2—uterine cancer	3.79e-05	0.000291	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKR1C3—uterine cancer	3.74e-05	0.000287	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.68e-05	0.000283	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SOCS3—uterine cancer	3.65e-05	0.00028	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PGR—uterine cancer	3.64e-05	0.00028	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—RRM2—uterine cancer	3.61e-05	0.000277	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—STAR—uterine cancer	3.57e-05	0.000274	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKR1B1—uterine cancer	3.57e-05	0.000274	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.53e-05	0.000271	CbGpPWpGaD
Irbesartan—JUN—Immune System—FGFR2—uterine cancer	3.52e-05	0.00027	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CDKN1B—uterine cancer	3.51e-05	0.00027	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—DCN—uterine cancer	3.51e-05	0.000269	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN2B—uterine cancer	3.49e-05	0.000268	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—YWHAE—uterine cancer	3.48e-05	0.000267	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NDUFB11—uterine cancer	3.43e-05	0.000263	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SRD5A2—uterine cancer	3.43e-05	0.000263	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IGF1R—uterine cancer	3.39e-05	0.000261	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CXCL8—uterine cancer	3.38e-05	0.000259	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.33e-05	0.000256	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FBXW7—uterine cancer	3.33e-05	0.000256	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ESR1—uterine cancer	3.32e-05	0.000255	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CTNNB1—uterine cancer	3.32e-05	0.000255	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP11A1—uterine cancer	3.31e-05	0.000254	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—MTHFR—uterine cancer	3.24e-05	0.000249	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PTEN—uterine cancer	3.23e-05	0.000248	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SMAD3—uterine cancer	3.19e-05	0.000245	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.15e-05	0.000242	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—NRAS—uterine cancer	3.14e-05	0.000241	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKR1C3—uterine cancer	3.12e-05	0.00024	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EP300—uterine cancer	3.08e-05	0.000237	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CXCL8—uterine cancer	3.07e-05	0.000236	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FGFR2—uterine cancer	3.04e-05	0.000234	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKR1B1—uterine cancer	2.93e-05	0.000225	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—STAR—uterine cancer	2.93e-05	0.000225	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCL2—uterine cancer	2.92e-05	0.000224	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STK11—uterine cancer	2.91e-05	0.000224	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKR1B1—uterine cancer	2.9e-05	0.000223	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—STAR—uterine cancer	2.9e-05	0.000223	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NRAS—uterine cancer	2.88e-05	0.000221	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.87e-05	0.00022	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—POLD1—uterine cancer	2.8e-05	0.000215	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—PIK3CA—uterine cancer	2.73e-05	0.00021	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SOCS3—uterine cancer	2.73e-05	0.000209	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—KRAS—uterine cancer	2.7e-05	0.000207	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NDUFB11—uterine cancer	2.65e-05	0.000203	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SRD5A2—uterine cancer	2.65e-05	0.000203	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKR1C1—uterine cancer	2.62e-05	0.000201	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDH1—uterine cancer	2.62e-05	0.000201	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN2B—uterine cancer	2.61e-05	0.0002	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ESR1—uterine cancer	2.6e-05	0.0002	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1R—uterine cancer	2.54e-05	0.000195	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KRAS—uterine cancer	2.48e-05	0.000191	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—STAR—uterine cancer	2.48e-05	0.00019	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKR1B1—uterine cancer	2.48e-05	0.00019	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PIK3CA—uterine cancer	2.48e-05	0.00019	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—NRAS—uterine cancer	2.46e-05	0.000189	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.45e-05	0.000188	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ERBB2—uterine cancer	2.44e-05	0.000187	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—STK11—uterine cancer	2.43e-05	0.000187	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP19A1—uterine cancer	2.43e-05	0.000187	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SMAD3—uterine cancer	2.38e-05	0.000183	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—RRM2—uterine cancer	2.33e-05	0.000179	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL8—uterine cancer	2.31e-05	0.000177	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—POLD1—uterine cancer	2.3e-05	0.000176	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—uterine cancer	2.29e-05	0.000176	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCL2—uterine cancer	2.29e-05	0.000176	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.28e-05	0.000175	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PIK3CA—uterine cancer	2.28e-05	0.000175	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—POLD1—uterine cancer	2.28e-05	0.000175	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FGFR2—uterine cancer	2.27e-05	0.000175	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—DCN—uterine cancer	2.27e-05	0.000174	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CDKN1B—uterine cancer	2.26e-05	0.000173	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AKT1—uterine cancer	2.23e-05	0.000171	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERBB2—uterine cancer	2.21e-05	0.00017	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.18e-05	0.000167	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKR1C1—uterine cancer	2.15e-05	0.000165	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PIK3CA—uterine cancer	2.14e-05	0.000165	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP11A1—uterine cancer	2.13e-05	0.000164	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKR1C1—uterine cancer	2.13e-05	0.000164	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CTNNB1—uterine cancer	2.13e-05	0.000164	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—uterine cancer	2.12e-05	0.000163	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—uterine cancer	2.11e-05	0.000162	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTEN—uterine cancer	2.08e-05	0.000159	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDKN1B—uterine cancer	2.05e-05	0.000157	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—uterine cancer	2.03e-05	0.000156	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKR1C3—uterine cancer	2.02e-05	0.000155	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EP300—uterine cancer	1.98e-05	0.000152	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—POLD1—uterine cancer	1.95e-05	0.000149	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PIK3CA—uterine cancer	1.95e-05	0.000149	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ESR1—uterine cancer	1.95e-05	0.000149	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTNNB1—uterine cancer	1.93e-05	0.000148	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—RRM2—uterine cancer	1.92e-05	0.000147	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—STAR—uterine cancer	1.92e-05	0.000147	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.92e-05	0.000147	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB2—uterine cancer	1.91e-05	0.000147	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—RRM2—uterine cancer	1.9e-05	0.000146	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTEN—uterine cancer	1.88e-05	0.000145	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—uterine cancer	1.88e-05	0.000144	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—uterine cancer	1.86e-05	0.000143	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—DCN—uterine cancer	1.86e-05	0.000143	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRAS—uterine cancer	1.85e-05	0.000142	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—DCN—uterine cancer	1.84e-05	0.000142	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—MTHFR—uterine cancer	1.83e-05	0.00014	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKR1C1—uterine cancer	1.82e-05	0.00014	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL8—uterine cancer	1.81e-05	0.000139	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTEN—uterine cancer	1.8e-05	0.000139	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—uterine cancer	1.8e-05	0.000138	CbGpPWpGaD
Irbesartan—JUN—Immune System—EP300—uterine cancer	1.8e-05	0.000138	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1B—uterine cancer	1.77e-05	0.000136	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.75e-05	0.000135	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—uterine cancer	1.75e-05	0.000134	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.74e-05	0.000133	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—EP300—uterine cancer	1.72e-05	0.000132	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCL2—uterine cancer	1.71e-05	0.000131	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—uterine cancer	1.68e-05	0.000129	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CTNNB1—uterine cancer	1.67e-05	0.000128	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.66e-05	0.000127	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.64e-05	0.000126	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—uterine cancer	1.63e-05	0.000125	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—RRM2—uterine cancer	1.62e-05	0.000125	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.61e-05	0.000124	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—uterine cancer	1.59e-05	0.000122	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—uterine cancer	1.59e-05	0.000122	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—DCN—uterine cancer	1.58e-05	0.000121	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—STK11—uterine cancer	1.57e-05	0.000121	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP19A1—uterine cancer	1.57e-05	0.000121	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EP300—uterine cancer	1.55e-05	0.000119	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—POLD1—uterine cancer	1.5e-05	0.000115	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP11A1—uterine cancer	1.48e-05	0.000114	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.47e-05	0.000113	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—uterine cancer	1.47e-05	0.000113	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—uterine cancer	1.47e-05	0.000112	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—uterine cancer	1.45e-05	0.000112	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—uterine cancer	1.45e-05	0.000111	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—uterine cancer	1.43e-05	0.00011	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—uterine cancer	1.42e-05	0.000109	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.41e-05	0.000108	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.41e-05	0.000108	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKR1C3—uterine cancer	1.4e-05	0.000108	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—uterine cancer	1.36e-05	0.000104	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—uterine cancer	1.35e-05	0.000104	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—uterine cancer	1.33e-05	0.000102	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1B—uterine cancer	1.32e-05	0.000102	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—STK11—uterine cancer	1.29e-05	9.9e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP19A1—uterine cancer	1.29e-05	9.9e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—STK11—uterine cancer	1.28e-05	9.81e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.28e-05	9.81e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—uterine cancer	1.27e-05	9.77e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—RRM2—uterine cancer	1.25e-05	9.62e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—uterine cancer	1.25e-05	9.61e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CTNNB1—uterine cancer	1.25e-05	9.59e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—uterine cancer	1.23e-05	9.44e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—uterine cancer	1.22e-05	9.35e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—DCN—uterine cancer	1.22e-05	9.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.2e-05	9.21e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—uterine cancer	1.2e-05	9.19e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MTHFR—uterine cancer	1.18e-05	9.06e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EP300—uterine cancer	1.16e-05	8.91e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—uterine cancer	1.15e-05	8.83e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.15e-05	8.8e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.14e-05	8.78e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—uterine cancer	1.11e-05	8.54e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—uterine cancer	1.1e-05	8.44e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—STK11—uterine cancer	1.09e-05	8.39e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP19A1—uterine cancer	1.09e-05	8.39e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—uterine cancer	1.09e-05	8.34e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—uterine cancer	1.09e-05	8.33e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.08e-05	8.31e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—uterine cancer	1.06e-05	8.17e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.04e-05	7.98e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—uterine cancer	1.04e-05	7.98e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.03e-05	7.87e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—uterine cancer	1.02e-05	7.8e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.78e-06	7.51e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—EP300—uterine cancer	9.69e-06	7.44e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MTHFR—uterine cancer	9.69e-06	7.44e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MTHFR—uterine cancer	9.61e-06	7.37e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—uterine cancer	9.39e-06	7.21e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—uterine cancer	9.35e-06	7.18e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—uterine cancer	8.59e-06	6.59e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.47e-06	6.5e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP19A1—uterine cancer	8.43e-06	6.47e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—STK11—uterine cancer	8.43e-06	6.47e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—uterine cancer	8.31e-06	6.38e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTHFR—uterine cancer	8.21e-06	6.3e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—uterine cancer	7.95e-06	6.1e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.23e-06	5.55e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—uterine cancer	7.17e-06	5.51e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—uterine cancer	7.02e-06	5.39e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—uterine cancer	6.57e-06	5.04e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTHFR—uterine cancer	6.34e-06	4.86e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—EP300—uterine cancer	6.26e-06	4.81e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—uterine cancer	5.86e-06	4.5e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—uterine cancer	5.39e-06	4.14e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—uterine cancer	5.34e-06	4.1e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—EP300—uterine cancer	5.14e-06	3.95e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—EP300—uterine cancer	5.1e-06	3.91e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—uterine cancer	4.63e-06	3.56e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—uterine cancer	4.57e-06	3.51e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—EP300—uterine cancer	4.36e-06	3.34e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—uterine cancer	3.8e-06	2.92e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—uterine cancer	3.78e-06	2.9e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—uterine cancer	3.77e-06	2.89e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—uterine cancer	3.52e-06	2.71e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—EP300—uterine cancer	3.36e-06	2.58e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—uterine cancer	3.22e-06	2.47e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—uterine cancer	3.11e-06	2.38e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—uterine cancer	3.08e-06	2.36e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—uterine cancer	2.63e-06	2.02e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.49e-06	1.91e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—uterine cancer	2.03e-06	1.56e-05	CbGpPWpGaD
